Jose M Mato

Dr. Jose M Mato

orcid

Research Focus & Metrics

Academic Career Length

54Years (1973-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2008 in Journal of Proteome Research
Verified
Journal Article
Closed access
JCJavier Conde-Vancells
Javier Conde-Vancells
EREva Rodriguez-Suarez
Eva Rodriguez-Suarez
NENieves Embade
Nieves Embade
DGDavid Gil
David Gil
Rune MatthiesenRune Matthiesen
Rune Matthiesen
JFJuan M Falcon-Perez
Juan M Falcon-Perez

1 October 2012 in Physiological Reviews
Verified
Journal Article
Closed access
PDF file
SLShelly Lu
Shelly Lu
JMJose M Mato
Jose M Mato
S-adenosylmethionine (AdoMet, also known as SAM and SAMe) is the principal biological methyl donor synthesized in all mammalian cells but most abundantly in the liver. Biosynthesis of AdoMet requires the enzyme methionine adenosyltransferase (MAT). In mammals, two genes, MAT1A that is largely expressed by normal liver and MAT2A that is expressed by all extrahepatic tissues, encode MAT. Patients with chronic liver disease have reduced MAT activity and AdoMet levels. Mice lacking Mat1a have reduced hepatic AdoMet levels and develop oxidative stress, steatohepatitis, and hepatocellular carcinoma (HCC). In these mice, several signaling pathways are abnormal that can contribute to HCC formation. However, injury and HCC also occur if hepatic AdoMet level is excessive chronically. This can result from inactive mutation of the enzyme glycine N-methyltransferase (GNMT). Children with GNMT mutation have elevated liver transaminases, and Gnmt knockout mice develop liver injury, fibrosis, and HCC. Thus a normal hepatic AdoMet level is necessary to maintain liver health and prevent injury and HCC. AdoMet is effective in cholestasis of pregnancy, and its role in other human liver diseases remains to be better defined. In experimental models, it is effective as a chemopreventive agent in HCC and perhaps other forms of cancer as well.

10 September 2021 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Closed access
PDF file
Mojgan MasoodiMojgan Masoodi
Mojgan Masoodi
Amalia GastaldelliAmalia Gastaldelli
Amalia Gastaldelli
THTuulia Hyötyläinen
Tuulia Hyötyläinen
EAEnara Arretxe
Enara Arretxe
CACristina Alonso
Cristina Alonso
Matej OresicMatej Oresic
Matej Oresic

6 July 2015 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
Jose Antonio Gomez-SanchezJose Antonio Gomez-Sanchez
Jose Antonio Gomez-Sanchez
LCLucy Carty
Lucy Carty
MIMarta Iruarrizaga-Lejarreta
Marta Iruarrizaga-Lejarreta
MPMarta Palomo-Irigoyen
Marta Palomo-Irigoyen
MVMarta Varela-Rey
Marta Varela-Rey
KJKristján R. Jessen
Kristján R. Jessen
Although Schwann cell myelin breakdown is the universal outcome of a remarkably wide range of conditions that cause disease or injury to peripheral nerves, the cellular and molecular mechanisms that make Schwann cell–mediated myelin digestion possible have not been established. We report that Schwann cells degrade myelin after injury by a novel form of selective autophagy, myelinophagy. Autophagy was up-regulated by myelinating Schwann cells after nerve injury, myelin debris was present in autophagosomes, and pharmacological and genetic inhibition of autophagy impaired myelin clearance. Myelinophagy was positively regulated by the Schwann cell JNK/c-Jun pathway, a central regulator of the Schwann cell reprogramming induced by nerve injury. We also present evidence that myelinophagy is defective in the injured central nervous system. These results reveal an important role for inductive autophagy during Wallerian degeneration, and point to potential mechanistic targets for accelerating myelin clearance and improving demyelinating disease.

1 January 1997 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
JMJose M Mato
Jose M Mato
LALuis Alvarez
Luis Alvarez
POPablo Ortiz
Pablo Ortiz
MPMaría Ángeles Pajares
María Ángeles Pajares

24 April 2001 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
SLShelly C. Lu
Shelly C. Lu
LALuis Alvarez
Luis Alvarez
ZHZong-Zhi Huang
Zong-Zhi Huang
LCLixin Chen
Lixin Chen
WAWei An
Wei An
JMJose M Mato
Jose M Mato
Liver-specific and nonliver-specific methionine adenosyltransferases (MATs) are products of two genes, MAT1A and MAT2A , respectively, that catalyze the formation of S -adenosylmethionine (AdoMet), the principal biological methyl donor. Mature liver expresses MAT1A , whereas MAT2A is expressed in extrahepatic tissues and is induced during liver growth and dedifferentiation. To examine the influence of MAT1A on hepatic growth, we studied the effects of a targeted disruption of the murine MAT1A gene. MAT1A mRNA and protein levels were absent in homozygous knockout mice. At 3 months, plasma methionine level increased 776% in knockouts. Hepatic AdoMet and glutathione levels were reduced by 74 and 40%, respectively, whereas S -adenosylhomocysteine, methylthioadenosine, and global DNA methylation were unchanged. The body weight of 3-month-old knockout mice was unchanged from wild-type littermates, but the liver weight was increased 40%. The Affymetrix genechip system and Northern and Western blot analyses were used to analyze differential expression of genes. The expression of many acute phase-response and inflammatory markers, including orosomucoid, amyloid, metallothionein, Fas antigen, and growth-related genes, including early growth response 1 and proliferating cell nuclear antigen, is increased in the knockout animal. At 3 months, knockout mice are more susceptible to choline-deficient diet-induced fatty liver. At 8 months, knockout mice developed spontaneous macrovesicular steatosis and predominantly periportal mononuclear cell infiltration. Thus, absence of MAT1A resulted in a liver that is more susceptible to injury, expresses markers of an acute phase response, and displays increased proliferation.